Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

Marginal-Zone Lymphomas The third most common lymphoma, MZL is usually indolent and
often a consequence of chronic antigenic stimulation from a pathogen such as Helicobacter …

Bruton tyrosine kinase inhibitors (BTKi) have transformed the therapeutic landscape of
chronic lymphocytic leukaemia (CLL) and non‐Hodgkin lymphoma. However, primary and …

Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity.
The clinical course is variable, multiple genes are mutated with no unifying mechanism, and …

Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase
(BTK) inhibitors has led to dramatic improvements in the management of B-cell …

Simple Summary Extranodal marginal zone lymphoma (EMZL) is an indolent
lymphoproliferative disease morphologically composed of small heterogeneous B …

Marginal zone lymphomas (MZL) are collectively the second most common indolent
lymphoma comprising 7% of all non-Hodgkin lymphomas with 7,460 patients diagnosed in …

Simple Summary The group of B-cell lymphomas primarily involving the lung encompasses
different histological entities with distinct biological aspects, while sharing some clinical and …

The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …

Acalabrutinib, a Bruton tyrosine kinase inhibitor, demonstrated greater selectivity and
improved safety versus ibrutinib in a head‐to‐head trial in relapsed/refractory (R/R) chronic …